- Home
- ELVN vs INVA Comparison
ELVN vs INVA Comparison
Compare ELVN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- INVA
- Stock Information
- Founded
- ELVN 2016
- INVA 1996
- Country
- ELVN United States
- INVA United States
- Employees
- ELVN N/A
- INVA N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- INVA Health Care
- Exchange
- ELVN Nasdaq
- INVA Nasdaq
- Market Cap
- ELVN 1.0B
- INVA 1.2B
- IPO Year
- ELVN 2020
- INVA 2004
- Fundamental
- Price
- ELVN $21.60
- INVA $18.28
- Analyst Decision
- ELVN Strong Buy
- INVA Buy
- Analyst Count
- ELVN 5
- INVA 1
- Target Price
- ELVN $37.80
- INVA N/A
- AVG Volume (30 Days)
- ELVN 269.1K
- INVA 585.7K
- Earning Date
- ELVN 03-13-2025
- INVA 02-27-2025
- Dividend Yield
- ELVN N/A
- INVA N/A
- EPS Growth
- ELVN N/A
- INVA 46.55
- EPS
- ELVN N/A
- INVA 0.99
- Revenue
- ELVN N/A
- INVA $352,745,000.00
- Revenue This Year
- ELVN N/A
- INVA $16.20
- Revenue Next Year
- ELVN N/A
- INVA N/A
- P/E Ratio
- ELVN N/A
- INVA $18.59
- Revenue Growth
- ELVN N/A
- INVA 21.46
- 52 Week Low
- ELVN $10.90
- INVA $14.33
- 52 Week High
- ELVN $30.03
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- ELVN 47.03
- INVA 50.49
- Support Level
- ELVN $20.40
- INVA $18.66
- Resistance Level
- ELVN $22.42
- INVA $19.06
- Average True Range (ATR)
- ELVN 1.25
- INVA 0.35
- MACD
- ELVN 0.06
- INVA 0.06
- Stochastic Oscillator
- ELVN 59.59
- INVA 48.96
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.